Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,135.29
(
-0.04%
)
US TECH 100
26,169.20
(
-0.13%
)
Dow Jones
49,483.95
(
-0.01%
)
Brent Oil
98.18
(
1.50%
)
Bitcoin
78,228.48
(
-0.01%
)
News Focus
News Focus
Post# of 648882
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Tuff-Stuff

Send PM Follow Ignore
Followers 217
Posts 247348
Boards Moderated 2
Alias Born 04/06/2006

Tuff-Stuff

Re: Tuff-Stuff post# 496514

Thursday, 01/31/2013 4:59:59 AM

Thursday, January 31, 2013 4:59:59 AM

Post# of 648882
Red>AstraZeneca (AZN): Q4 EPS of $1.56 beats by $0.21. Revenues of $7.28B (-16% Y/Y) beat by $80M.

Profit excluding items -8% to $1.94B, with a patent cliff hurting earnings in Q4 and expected to continue to do so this year. As such, AstraZeneca warns of a "mid-to-high single digit percentage decline in revenue for 2013," (vs consensus of -3%) and that earnings will drop "significantly more than revenue" as operating costs rise.

Concentrate, and ASK the 8-Ball!

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today